Progress

Inclusions closed on 08/30/2021
Analyses finalized on 09/30/2021
Article in submission

Presentation and objectives

Document the real-life use of Elocta®: compare the treatment modalities of these patients receiving Elocta® with the previous treatment modality before switchover

Persons concerned
Type of data collected
(*data excluding FranceCoag)

Hemophilia A patients (any age, any degree of severity, with or without inhibitor) included in the general cohort or in the PUPs cohort, and treated with Elocta® for at least 6 months.
Treatments, therapeutic regimens, demographics, bleeding and surgery, inhibitors

Regulatory approvals
Information note

Favourable opinion from FranceCoag’s Scientific Committee
MR004 declared to the CNIL

NI Children
NI Teenagers
NI Parents

Project sponsor (financier)

Swedish Orphan Biovitrum Ab (SOBI)